{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:57:43Z","timestamp":1792508263246,"version":"4.5.0"},"reference-count":69,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"6","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":132,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Current clinical practice guidelines for the treatment of posttraumatic stress disorder offer varying recommendations regarding the use of pharmacotherapy. Many direct head-to-head comparisons of pharmacotherapy are lacking, and recommendations are based on meta-analyses and small trials. While selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors are considered first-line pharmacotherapy, clear distinctions do not exist when considering other classes of psychotropic medications. Ultimately, when selecting an appropriate medication for a patient diagnosed with posttraumatic stress disorder, the clinician needs to consider the current symptomatology being experienced, comorbid conditions, and evidence for efficacy of specific treatments prior to initiating medications.<\/jats:p>","DOI":"10.9740\/mhc.2019.11.373","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T15:30:43Z","timestamp":1574868643000},"page":"373-382","source":"Crossref","is-referenced-by-count":46,"title":["Treatment of posttraumatic stress disorder: Focus on pharmacotherapy"],"prefix":"10.9740","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7184-2895","authenticated-orcid":false,"given":"Megan","family":"Ehret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"key":"2020060307350411800_i2168-9709-9-6-373-b01","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association;2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"7","key":"2020060307350411800_i2168-9709-9-6-373-b02","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamapsychiatry.2016.0600","article-title":"Risk factors, methods, and timing of suicide attempts among US army soldiers","volume":"73","author":"Ursano","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"2020060307350411800_i2168-9709-9-6-373-b03","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jpsychires.2016.06.022","article-title":"The association between post-traumatic stress disorder and lifetime DSM-5 psychiatric disorders among veterans: data from the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III)","volume":"82","author":"Smith","year":"2016","journal-title":"J Psychiatr Res"},{"issue":"3","key":"2020060307350411800_i2168-9709-9-6-373-b04","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.janxdis.2010.11.010","article-title":"Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"25","author":"Pietrzak","year":"2011","journal-title":"J Anxiety Disord"},{"issue":"8","key":"2020060307350411800_i2168-9709-9-6-373-b05","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00127-016-1208-5","article-title":"The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III","volume":"51","author":"Goldstein","year":"2016","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"5","key":"2020060307350411800_i2168-9709-9-6-373-b06","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11920-015-0575-z","article-title":"Prevalence of, risk factors for, and consequences of posttraumatic stress disorder and other mental health problems in military populations deployed to Iraq and Afghanistan","volume":"17","author":"Ramchand","year":"2015","journal-title":"Curr Psychiatry Rep"},{"key":"2020060307350411800_i2168-9709-9-6-373-b07","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patient with acute stress disorder and posttraumatic stress disorder. Arlington (VA): American Psychiatric Association;2004."},{"key":"2020060307350411800_i2168-9709-9-6-373-b08","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder: guideline watch. Arlington (VA): American Psychiatric Association;2009."},{"issue":"5","key":"2020060307350411800_i2168-9709-9-6-373-b09","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder. A revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"J Psychopharmacol"},{"key":"2020060307350411800_i2168-9709-9-6-373-b10","unstructured":"Australian Centre for Posttraumatic Mental Health. Australian guidelines for the treatment of acute stress disorder and posttraumatic stress disorder. Melbourne, Victoria: Australian Centre for Posttraumatic Mental Health;2013."},{"issue":"Suppl 1","key":"2020060307350411800_i2168-9709-9-6-373-b11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"key":"2020060307350411800_i2168-9709-9-6-373-b12","unstructured":"Veterans Health Administration, Department of Defense. VA\/DoD clinical practice guideline for the management of post-traumatic stress. Washington: Veterans Health Administration, Department of Defense;2017."},{"key":"2020060307350411800_i2168-9709-9-6-373-b13","article-title":"Post-traumatic stress disorder (NICE Quality Standard NG116)","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"2020060307350411800_i2168-9709-9-6-373-b14","unstructured":"Hoffman\n              V\n            , MiddletonJC, FeltnerC, GaynesBN, WeberRP, BannC, et al. \n          Psychological and pharmacological treatments for adults with posttraumatic stress disorder: a systematic review update. Comparative Effectiveness Review No. 207. Rockville (MD): Agency for Healthcare Research and Quality;2018."},{"key":"2020060307350411800_i2168-9709-9-6-373-b15","article-title":"Clinical practice guideline for the treatment of Posttraumatic Stress Disorder (PTSD) in adults","year":"2017","journal-title":"American Psychological Association, Guideline Development Panel for the Treatment of PTSD in Adults"},{"issue":"9","key":"2020060307350411800_i2168-9709-9-6-373-b16","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/da.22511","article-title":"Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments","volume":"33","author":"Lee","year":"2016","journal-title":"Depress Anxiety"},{"issue":"6","key":"2020060307350411800_i2168-9709-9-6-373-b17","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.4088\/JCP.12r08225","article-title":"Meta-analysis of the efficacy of treatments for posttraumatic stress disorder","volume":"74","author":"Watts","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"2020060307350411800_i2168-9709-9-6-373-b18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1176\/appi.ps.59.10.1184","article-title":"Pharmacologic treatment of posttraumatic stress disorder among privately insured Americans","volume":"59","author":"Harpaz-Rotem","year":"2008","journal-title":"Psychiatr Serv"},{"issue":"2","key":"2020060307350411800_i2168-9709-9-6-373-b19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1192\/bjp.bp.114.148551","article-title":"Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis","volume":"206","author":"Hoskins","year":"2015","journal-title":"Br J Psychiatry"},{"issue":"12","key":"2020060307350411800_i2168-9709-9-6-373-b20","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1017\/S003329171700349X","article-title":"Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis","volume":"48","author":"Cipriani","year":"2018","journal-title":"Psychol Med"},{"issue":"3","key":"2020060307350411800_i2168-9709-9-6-373-b21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0897190015624862","article-title":"Should we be worried about QTc prolongation using citalopram? A review","volume":"30","author":"Hutton","year":"2017","journal-title":"J Pharm Pract"},{"issue":"3","key":"2020060307350411800_i2168-9709-9-6-373-b22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/01.jcp.0000125685.82219.1a","article-title":"A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder","volume":"24","author":"Davis","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"2020060307350411800_i2168-9709-9-6-373-b23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/da.20008","article-title":"Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder","volume":"19","author":"McRae","year":"2004","journal-title":"Depress Anxiety"},{"key":"2020060307350411800_i2168-9709-9-6-373-b24","first-page":"1","article-title":"Nefazodone versus sertraline in treatment of posttraumatic stress disorder","volume":"12","author":"Saygin","year":"2002","journal-title":"Bull Clin Psychopharmacol"},{"issue":"6","key":"2020060307350411800_i2168-9709-9-6-373-b25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/00005053-199106000-00011","article-title":"Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine","volume":"179","author":"Kosten","year":"1991","journal-title":"J Nerv Ment Dis"},{"issue":"12","key":"2020060307350411800_i2168-9709-9-6-373-b26","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2016.15070967","article-title":"Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial","volume":"173","author":"Villarreal","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"5","key":"2020060307350411800_i2168-9709-9-6-373-b27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jama.2011.1080","article-title":"Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial","volume":"306","author":"Krystal","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"2020060307350411800_i2168-9709-9-6-373-b28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophr Bull"},{"issue":"1","key":"2020060307350411800_i2168-9709-9-6-373-b29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"29","author":"Bostwick","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2020060307350411800_i2168-9709-9-6-373-b30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/JCP.0b013e318160f83b","article-title":"Divalproex in the treatment of posttraumatic stress disorder","volume":"28","author":"Davis","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"2020060307350411800_i2168-9709-9-6-373-b31","unstructured":"Topamax (topiramate) [package insert]. Titusville (NJ): Janssen Pharmaceuticals; 2012."},{"key":"2020060307350411800_i2168-9709-9-6-373-b32","unstructured":"Lamictal (lamotrigine) [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2015."},{"key":"2020060307350411800_i2168-9709-9-6-373-b33","article-title":"Depakote (divalproex sodium) [package insert]","year":"2017"},{"key":"2020060307350411800_i2168-9709-9-6-373-b34","article-title":"Posttraumatic stress disorder field trial: evaluation of PTSD construct criteria A through E","author":"Kilpatrick","year":"1994","journal-title":"DSM-IV Sourcebook"},{"issue":"6","key":"2020060307350411800_i2168-9709-9-6-373-b35","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.5664\/jcsm.7178","article-title":"Position paper for the treatment of nightmare disorder in adults: an American Academy of Sleep Medicine Position Paper","volume":"14","author":"Morgenthaler","year":"2018","journal-title":"J Clin Sleep Med"},{"key":"2020060307350411800_i2168-9709-9-6-373-b36","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien (IL): American Academy of Sleep Medicine;2014."},{"issue":"5","key":"2020060307350411800_i2168-9709-9-6-373-b37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/jts.20565","article-title":"A guide to guidelines for the treatment of PTSD and related conditions","volume":"23","author":"Forbes","year":"2010","journal-title":"J Trauma Stress"},{"issue":"2","key":"2020060307350411800_i2168-9709-9-6-373-b38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1176\/appi.ajp.160.2.371","article-title":"Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study","volume":"160","author":"Raskind","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"8","key":"2020060307350411800_i2168-9709-9-6-373-b39","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.biopsych.2006.06.032","article-title":"A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder","volume":"61","author":"Raskind","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"9","key":"2020060307350411800_i2168-9709-9-6-373-b40","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1176\/appi.ajp.2013.12081133","article-title":"A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan","volume":"170","author":"Raskind","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"2","key":"2020060307350411800_i2168-9709-9-6-373-b41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpsychores.2011.11.010","article-title":"Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US Military Veterans","volume":"72","author":"Germain","year":"2012","journal-title":"J Psychosom Res"},{"issue":"6","key":"2020060307350411800_i2168-9709-9-6-373-b42","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1507598","article-title":"Trial of prazosin for post-traumatic stress disorder in military veterans","volume":"378","author":"Raskind","year":"2018","journal-title":"N Engl J Med"},{"key":"2020060307350411800_i2168-9709-9-6-373-b43","article-title":"Cooperative Studies Program #563-Prazosin and Combat Trauma PTSD (PACT)","journal-title":"ClinicalTrials.gov"},{"issue":"6","key":"2020060307350411800_i2168-9709-9-6-373-b44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.biopsych.2007.07.001","article-title":"Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study","volume":"63","author":"Taylor","year":"2008","journal-title":"Biol Psychiatry"},{"issue":"4","key":"2020060307350411800_i2168-9709-9-6-373-b45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000362243","article-title":"Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder","volume":"69","author":"Ahmadpanah","year":"2014","journal-title":"Neuropsychobiology"},{"issue":"6","key":"2020060307350411800_i2168-9709-9-6-373-b46","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/01.pra.0000364287.63210.92","article-title":"Preliminary findings concerning the use of prazosin for the treatment of posttraumatic nightmares in a refugee population","volume":"15","author":"Boynton","year":"2009","journal-title":"J Psychiatr Pract"},{"issue":"6","key":"2020060307350411800_i2168-9709-9-6-373-b47","doi-asserted-by":"publisher","first-page":"513","DOI":"10.7205\/MILMED.170.6.513","article-title":"Clinical case series: the use of prazosin for combat-related recurrent nightmares among operation Iraqi freedom combat veterans","volume":"170","author":"Daly","year":"2005","journal-title":"Mil Med"},{"issue":"3","key":"2020060307350411800_i2168-9709-9-6-373-b48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/0891988703256050","article-title":"Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder","volume":"16","author":"Peskind","year":"2003","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"2","key":"2020060307350411800_i2168-9709-9-6-373-b49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4088\/JCP.v61n0208","article-title":"The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases","volume":"61","author":"Raskind","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"2020060307350411800_i2168-9709-9-6-373-b50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/00004714-200202000-00013","article-title":"The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder","volume":"22","author":"Taylor","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"2020060307350411800_i2168-9709-9-6-373-b51","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1034\/j.1600-0447.2003.00065.x","article-title":"Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports","volume":"107","author":"Jakovljevi\u0107","year":"2003","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"2020060307350411800_i2168-9709-9-6-373-b52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/da.20187","article-title":"Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD","volume":"23","author":"David","year":"2006","journal-title":"Depress Anxiety"},{"issue":"3","key":"2020060307350411800_i2168-9709-9-6-373-b53","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/00004630-200105000-00005","article-title":"The effectiveness of risperidone on acute stress symptoms in adult burn patients: a preliminary retrospective pilot study","volume":"22","author":"Stanovic","year":"2001","journal-title":"J Burn Care Rehabil"},{"issue":"3","key":"2020060307350411800_i2168-9709-9-6-373-b54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/01.yic.0000185021.48279.00","article-title":"Aripiprazole in the management of post-traumatic stress disorder symptoms in returning Global War on Terrorism veterans","volume":"21","author":"Lambert","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"2020060307350411800_i2168-9709-9-6-373-b55","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.neuropharm.2011.02.029","article-title":"Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence","volume":"62","author":"Nappi","year":"2012","journal-title":"Neuropharmacology"},{"issue":"6","key":"2020060307350411800_i2168-9709-9-6-373-b56","first-page":"236","article-title":"Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment","volume":"51","author":"Braun","year":"1990","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"2020060307350411800_i2168-9709-9-6-373-b57","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1345\/aph.1E043","article-title":"Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder","volume":"38","author":"Cates","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"5","key":"2020060307350411800_i2168-9709-9-6-373-b58","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0278-2391(91)90180-t","article-title":"Disinhibitory reactions to benzodiazepines: a review","volume":"49","author":"van der Bijl","year":"1991","journal-title":"J Oral Maxillofac Surg"},{"issue":"11","key":"2020060307350411800_i2168-9709-9-6-373-b59","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1177\/0269881109106927","article-title":"Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics","volume":"24","author":"Nutt","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"7","key":"2020060307350411800_i2168-9709-9-6-373-b60","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.09m05607gry","article-title":"Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Pollack","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2020060307350411800_i2168-9709-9-6-373-b61","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/hup.2522","article-title":"Pharmacology for sleep disturbance in PTSD","volume":"31","author":"Lipinska","year":"2016","journal-title":"Hum Psychopharmacol"},{"issue":"8","key":"2020060307350411800_i2168-9709-9-6-373-b62","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/da.22384","article-title":"Combined mirtazapine and SSRI treatment of PTSD: a placebo-controlled trial","volume":"32","author":"Schneier","year":"2015","journal-title":"Depress Anxiety"},{"key":"2020060307350411800_i2168-9709-9-6-373-b63","unstructured":"Ambien (zolpidem) [package insert]. Bridgewater (NJ): Sanofi-Aventis; c2008."},{"issue":"03","key":"2020060307350411800_i2168-9709-9-6-373-b64","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4088\/JCP.10m06775","article-title":"Declining benzodiazepine use in veterans with posttraumatic stress disorder","volume":"73","author":"Lund","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"2020060307350411800_i2168-9709-9-6-373-b65","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1176\/appi.ajp.2014.13121625","article-title":"A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans","volume":"171","author":"Rothbaum","year":"2014","journal-title":"Am J Psychiatry"},{"key":"2020060307350411800_i2168-9709-9-6-373-b66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0264180100000412","article-title":"The natural history of tolerance to the benzodiazepines","volume":"13","author":"Higgitt","year":"1988","journal-title":"Psychol Med Monogr Suppl"},{"issue":"2","key":"2020060307350411800_i2168-9709-9-6-373-b67","first-page":"1533","article-title":"Clinical Pharmacology and therapeutics of benzodiazepines","volume":"118","author":"Sellers","year":"1978","journal-title":"Can Med Assoc J"},{"issue":"4","key":"2020060307350411800_i2168-9709-9-6-373-b68","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.euroneuro.2008.12.004","article-title":"Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD","volume":"19","author":"Matar","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"2020060307350411800_i2168-9709-9-6-373-b69","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0091-3057(96)00110-4","article-title":"Diazepam enhances conditioned defeat in hamsters (Mesocricetus auratus)","volume":"55","author":"Hebert","year":"1996","journal-title":"Pharmacol Biochem Behav"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/6\/373\/2427830\/mhc_2019_11_373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/6\/373\/2427830\/mhc_2019_11_373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:25:53Z","timestamp":1731687953000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/9\/6\/article-p373.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2019.11.373","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}